Manufacturers spend billions of dollars each year pursuing opportunities within the lucrative glaucoma pharmaceutical industry, but largely ignore the needs of glaucoma surgeons and their patients.
With its platform product undergoing the US regulatory approval cycle, and a host of follow-on devices in various stages of design, development, and patent protection, Mobius Therepeutics aims to correct this imbalance and provide new hope to the tens of thousands of glaucoma patients surgically treated each year.
Currently defined procedures will be enhanced with greater precision and convenience. New devices and implants, respectful of the needs and physiology of patients, will redefine the ways in which glaucoma can be treated.
Mobius™ founder, Ed Timm, is a medical/surgical device industry veteran with broad management experience spanning sales, marketing, international distribution, strategic planning, and business development.
He has gained significant experience in ophthalmic surgery, with a track record of nearly twenty years of continuous governance and innovation. Mobius Therapeutics aims to apply this same measure of competence and focused service to the glaucoma surgery arena.
Read up on the latest clinical and non-clinical studies and research papers related to glaucoma surgery.
What is glaucoma and what are the current treatment options for this condition?
Learn about upcoming conferences, seminars and events in the glaucoma surgery community.